

Docket No.: 102258.288US5

PATENT/OFFICIAL

IFW

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Is re Application of

Jay N. COHN et al.

Serial No. 10/824,607

Filed: April 15, 2004

:  
:  
:  
:  
: Group Art Unit: 1614  
:  
: Examiner:

For: KITS OF HYDRALAZINE COMPOUNDS AND ISOSORBIDE DINITRATE  
AND/OR ISOSORBIDE MONONITRATE

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Honorable Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom. Copies of any cited U.S. Patents and U.S. Patent Publications are not being submitted in accordance with 37 CFR 1.98(a)(2)(i).

This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

In accordance with 37 C.F.R. § 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search had been made or that information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item, and Applicant reserves the


right to prove that the date of publication is in fact different.

Applicants' representative certifies that some of the enclosed documents were cited in a communication from the European Patent Office in a counterpart foreign application not more than three months before the filing date of this Information Disclosure Statement. A copy of the European Search Report is enclosed.

No fee is believed to be required, however, the Commissioner is authorized to charge any deficiency in any fees pursuant to 37 CFR § 1.17 associated with this communication and to credit any excess payment to Deposit Account No. 08-0219.

Respectfully submitted,

WILMER CUTLER PICKERING HALE AND DORR LLP


  
Edward D. Grieff  
Registration No. 38,898

1455 Pennsylvania Avenue, NW  
Washington, DC 20004

TEL 202.942.8400 EDG/mgm

FAX 202.942.8484

Date: September 22, 2004

<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>   (PTO-1449)				ATTY. DOCKET NO. 102258.288US5		SERIAL NO. 10/824,607	
				APPLICANT Jay N. COHN et al.			
				FILING DATE April 15, 2004		GROUP 1614	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
<b>OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	Levine, Barry T. et al. September 1998. "Paradoxical Hypertension after Reversal of Heart Failure in Patients Treated with Intensive Vasodilator Therapy." <i>American Journal of Hypertension</i> , Vol. 11, No. 9. pp. 1041-1047.						
	Harjai, Kishore J. et al. February 1999. "Does Patient Race Influence Utilization of Effective Medical Therapy for Heart Failure?" <i>Journal of the American College of Cardiology</i> , Vol. 33, No. 2, Supplement A. pp. 179A.						
	25 June 2004. Supplementary European Search Report from European Patent Application No. 00961745.7.						
EXAMINER				DATE CONSIDERED			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.